MINNEAPOLIS, May 20, 2009 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced the U.S. launch of its new Muskie guidewires. The Muskie guidewires are a new line of 0.014" guidewires with a range of distal tip stiffness that allows a physician to select an appropriate guidewire for crossing highly stenosed lesions. The Muskie guidewires have received 510K clearance from the FDA and are intended for use in the coronary and peripheral vasculature.
"The Muskie guidewires are an important addition to our Access Products product line, consistent with our offering of clinical niche solutions in the area of challenging interventions. As our fifth new product launch to date in 2009, the Muskie guidewires are yet another example of our efficient ability to bring solutions to our customers' specific clinical needs, while utilizing the strength of our U.S. direct sales force to introduce and support our complete product portfolio for percutaneous procedures," commented Howard Root, Chief Executive Officer.
About Vascular Solutions
Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of five major categories: hemostat (blood clotting) products, extraction (clot removal) catheters, vein products, specialty catheters and access products. Vascular Solutions delivers its proprietary and distributed products to interventional cardiologists, interventional radiologists and vascular surgeons through its direct U.S. sales force and international distributor network.
The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2008 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of sustained profitability, exposure to intellectual property claims, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.
For further information, connect to www.vascularsolutions.com.